Theriva Biologics Inc. has filed a prospectus supplement with the Securities and Exchange Commission, allowing for the offer and sale of up to $2,534,352 worth of its common stock. The sales will be conducted through A.G.P./Alliance Global Partners, acting as the sales agent in an "at the market offering." The prospectus is linked to Theriva's Registration Statement, which became effective on September 25, 2024. The sales agent will earn a commission of up to 3% on the gross sales price per share. The company has also agreed to provide indemnification and contribution for certain liabilities related to the offering. This filing does not constitute an offer to sell or solicitation to buy securities in any state where such actions would be unlawful.